Inhibrx Biosciences (INBX) Shares Outstanding (Weighted Average) (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Shares Outstanding (Weighted Average) data on file, last reported at $2.0 million in Q4 2025.

• Shares Outstanding (Weighted Average) for Q4 2025 came in at $2.0 million, down 86.49% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.0 million (down 86.49% YoY), and the FY2025 annual result was $2.0 million, changed N/A from the prior year.
• Shares Outstanding (Weighted Average) declined to $2.0 million in Q4 2025 per INBX's latest filing, from $15.5 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $15.5 million in Q3 2025 and troughed at $2.0 million in Q4 2025.
• A 3-year average of $12.3 million and a median of $13.6 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) gained 25.62% in 2024, then plunged 86.49% in 2025.
• A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $11.8 million in 2023, then climbed by 25.62% to $14.8 million in 2024, then sank by 86.49% to $2.0 million in 2025.
• Business Quant data shows INBX's Shares Outstanding (Weighted Average) at $2.0 million in Q4 2025, $15.5 million in Q3 2025, and $15.5 million in Q2 2025.